Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4367MR)

This product GTTS-WQ4367MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4367MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8092MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ4236MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ887MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ3175MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ1899MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ9237MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ4077MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ6005MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW